GTx (NASDAQ: GTXI) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability.
Institutional and Insider Ownership
9.5% of GTx shares are owned by institutional investors. Comparatively, 51.8% of Curis shares are owned by institutional investors. 41.2% of GTx shares are owned by insiders. Comparatively, 4.1% of Curis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
GTx has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Curis has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings for GTx and Curis, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GTx | 0 | 1 | 0 | 0 | 2.00 |
| Curis | 0 | 0 | 4 | 0 | 3.00 |
GTx presently has a consensus price target of $1.00, suggesting a potential downside of 82.24%. Curis has a consensus price target of $6.67, suggesting a potential upside of 311.52%. Given Curis’ stronger consensus rating and higher probable upside, analysts clearly believe Curis is more favorable than GTx.
Profitability
This table compares GTx and Curis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GTx | N/A | -192.51% | -145.17% |
| Curis | -836.18% | -236.43% | -88.44% |
Valuation & Earnings
This table compares GTx and Curis’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| GTx | N/A | N/A | -$26.47 million | ($1.73) | -3.25 |
| Curis | $8.31 million | 28.05 | -$48.51 million | ($0.50) | -3.24 |
GTx has higher revenue, but lower earnings than Curis. GTx is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.
Summary
Curis beats GTx on 8 of the 12 factors compared between the two stocks.
GTx Company Profile
GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.
Curis Company Profile
Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
